Ultralife (ULBI) AI Stock Analysis

• Market Cap: $94.73M
• Dividend Yield: N/A
• Average Volume (3M): 48.89K
• Price to Earnings (P/E): 55.3
• Beta (1Y): 1.65
• Revenue Growth: 12.94%
• EPS Growth: -81.09%
• Country: US
• Employees: 671
• Sector: Industrials
• Sector Strength: 72
• Industry: Electrical Equipment & Parts
• EPS (TTM): -0.07
• Shares Outstanding: 16,648,947
• 10 Day Avg. Volume: 60,683
• 30 Day Avg. Volume: 48,890
• PEG Ratio: -1.43
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 0.75
• P/FCF Ratio: 8.39
• Enterprise Value/Market Cap: 1.67
• Enterprise Value/Revenue: 0.85
• Enterprise Value/Gross Profit: 3.55
• Enterprise Value/Ebitda: 13.74
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $6.00 ▲(3.45% Upside)

Ultralife's overall stock score is driven by moderate financial performance and mixed earnings call results. The stock's technical indicators suggest bearish momentum, and its high P/E ratio indicates overvaluation. Despite revenue growth and strategic initiatives, challenges in profitability and cash flow weigh heavily on the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for Ultralife's products, enhancing its market position and supporting long-term business expansion.

Backlog Growth

A growing backlog suggests strong future sales and demand, providing revenue visibility and stability for the company.

New Product Development

Investment in new products can drive future growth and competitiveness, ensuring the company remains innovative and relevant in its industry.

Negative Factors

Operating Loss

Operating losses indicate financial strain and inefficiencies, which could impact long-term profitability and require strategic adjustments.

Gross Margin Decline

Declining gross margins suggest increased production costs or pricing pressures, potentially reducing profitability and competitive edge.

Increased Operating Expenses

Rising operating expenses can strain financial resources and reduce net income, impacting the company's ability to invest in growth opportunities.

Ultralife Business Overview & Revenue Model

Company Description

Ultralife Corporation (ULBI) is a global provider of a diverse range of power and communications solutions, primarily serving the defense, medical, and industrial sectors. The company specializes in the design and manufacture of advanced battery systems, communication and power management systems, and a variety of accessories for portable power applications. With a strong focus on innovation and quality, Ultralife is committed to delivering reliable and sustainable power solutions to meet the demanding needs of its customers.

How the Company Makes Money

Ultralife generates revenue through multiple key streams, primarily centered around its core product offerings. The company sells rechargeable and non-rechargeable batteries, battery management systems, and communications equipment, catering to both military and commercial markets. A significant portion of its income comes from contracts with governmental defense agencies and commercial partnerships, which often include long-term agreements for supply and support services. Additionally, Ultralife capitalizes on its technological advancements by developing customized solutions for specific client needs, allowing for premium pricing on specialized products. Strategic alliances and collaborations with other technology firms also contribute to its revenue, enhancing its market reach and product capabilities.

Ultralife Financial Statement Overview

Summary

Ultralife shows moderate financial health with stable revenue growth but declining profitability margins. The balance sheet is strong with low leverage, enhancing financial stability. However, cash flow challenges, particularly in free cash flow growth, pose potential risks.

Income Statement

Ultralife's income statement shows moderate revenue growth with a TTM increase of 4.29%. However, profitability margins have declined, with a TTM net profit margin of 0.92% compared to 3.84% in the previous year. The gross profit margin also decreased slightly from 25.73% to 23.89%. The EBIT and EBITDA margins have similarly contracted, indicating pressure on operational efficiency.

Balance Sheet

The balance sheet reflects a strong equity position with a debt-to-equity ratio of 0.03 in TTM, significantly improved from 0.40 in the previous year. Return on equity has decreased to 1.26% from 4.71%, suggesting reduced profitability on equity. The equity ratio remains robust, indicating financial stability.

Cash Flow

Cash flow analysis reveals challenges, with a significant decline in free cash flow growth at -35.78% in TTM. The operating cash flow to net income ratio is 0.51, indicating moderate cash generation relative to net income. The free cash flow to net income ratio is relatively healthy at 0.81, but overall cash flow performance is weakened.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	186.53M	164.46M	158.64M	131.84M	98.27M	107.71M
Gross Profit	44.56M	42.31M	39.20M	29.40M	24.64M	29.16M
EBITDA	11.52M	14.40M	15.04M	4.96M	3.63M	10.39M
Net Income	1.72M	6.31M	7.20M	-119.00K	-234.00K	5.23M
Balance Sheet
Total Assets	222.25M	220.45M	178.28M	168.43M	159.54M	137.70M
Cash, Cash Equivalents and Short-Term Investments	9.26M	6.85M	10.28M	5.71M	8.41M	10.65M
Total Debt	53.80M	58.39M	29.16M	23.51M	23.47M	3.56M
Total Liabilities	84.81M	86.26M	52.85M	52.03M	41.80M	20.78M
Stockholders Equity	137.26M	134.00M	125.33M	116.28M	117.62M	116.80M
Cash Flow
Free Cash Flow	8.93M	14.70M	-623.00K	-2.94M	1.51M	18.62M
Operating Cash Flow	12.52M	16.64M	1.93M	-1.26M	4.33M	21.72M
Investing Cash Flow	-51.61M	-49.95M	-2.55M	-1.68M	-26.33M	-2.98M
Financing Cash Flow	41.72M	29.86M	5.49M	518.00K	19.64M	-15.69M

Ultralife Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ULBI, the sentiment is Negative. The current price of 5.8 is below the 20-day moving average (MA) of 5.97, below the 50-day MA of 6.50, and below the 200-day MA of 6.58, indicating a bearish trend. The MACD of -0.31 indicates Negative momentum. The RSI at 42.71 is Neutral, neither overbought nor oversold. The STOCH value of 79.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ULBI.

Ultralife Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ESP	82 Outperform	$114.70M	12.41	18.65%	2.52%	4.90%	31.13%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
ULBI	55 Neutral	$94.73M	55.30	1.26%	―	12.94%	-81.09%
SKYX	55 Neutral	$244.56M	―	-1421.39%	―	7.06%	12.25%
CBAT	50 Neutral	$78.94M	-8.75	-5.16%	―	-22.02%	-156.65%
FLUX	42 Neutral	$32.22M	-3.34	―	―	2.14%	5.01%
DFLI	40 Underperform	$104.96M	―	―	―	18.24%	24.49%

Ultralife Corporate Events

Ultralife Corporation Reports Revenue Growth Amidst Challenges

Ultralife Corporation is a Delaware-based company operating in the battery and energy products sector, known for its innovative solutions in portable power and communications systems. In its latest earnings report for the quarter ending September 30, 2025, Ultralife reported a revenue increase to $43.4 million, up from $35.7 million in the same period last year, driven by strong performance in its Battery & Energy Products segment. Despite the revenue growth, the company faced a net loss of $1.2 million, compared to a net income of $258,000 in the previous year, primarily due to increased operating expenses and interest costs. Key financial highlights include a gross profit of $9.6 million and a significant rise in research and development expenses to $2.9 million, reflecting the company’s commitment to innovation. Looking ahead, Ultralife’s management remains focused on leveraging its recent acquisition of Electrochem Solutions to enhance operational efficiency and expand market reach, positioning the company for potential growth in the coming quarters.

Ultralife Corporation Delays Q3 10-Q Filing

Ultralife Corporation has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The delay is primarily due to the recent transition of Electrochem Solutions, Inc.’s financial systems to Ultralife’s systems following its acquisition from Integer Holdings Corporation. This transition necessitated additional time to finalize third-quarter results and complete the review by independent accountants. The company anticipates filing the report by November 17, 2025, within the five-day extension period allowed. Ultralife does not expect any significant changes in financial results compared to the previous year. The notification was signed by Philip A. Fain, Chief Financial Officer & Treasurer, indicating ongoing compliance efforts.

The most recent analyst rating on (ULBI) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Ultralife stock, see the ULBI Stock Forecast page.